TG Therapeutics (TGTX) Stock Forecast & Price Target

TG Therapeutics Inc. demonstrates a promising financial outlook driven by the strong market performance of its approved treatment, BRIUMVI, which currently accounts for approximately 30% of new prescriptions in the intravenous (IV) market and is expected to gain further market share, particularly from the established product, Ocrevus. Additionally, the company has observed a 6% increase in prescription volume over the past three months, reflecting positive trends in demand for its therapies. The anticipated U.S. revenue of approximately $570-575 million from BRIUMVI in 2025, three years post-launch, further underscores the company's strong market execution and potential for robust financial growth.

TG Therapeutics’s stock outlook remains negative due to concerns over slower growth projections, as reflected in the company's guidance indicating that revenue growth from the second quarter of 2025 to the third quarter will lag behind the growth from the third to the fourth quarter. Furthermore, while there has been a noted improvement in annualized relapse rates (ARR) for patients transitioning to BRIUMVI, this alone may not sufficiently drive significant sales growth compared to competitors like Kesimpta, which has demonstrated robust revenue generation reaching $2.2 billion within five years post-approval. The overall financial performance is compounded by the potential challenges of achieving sustained market penetration and competitive positioning within a rapidly evolving therapeutic landscape.